- Country: USA
- Summary: TECHNOLOGY/BUSINESS OPPORTUNITY Protein mediated immune cell engineering
- UST Ref No: 114816299
- Deadline: 14 Mar 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: IL-13908
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Opportunity:
Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop and commercialize its “protein mediated immune cell engineering” technology.
Background:
Chimeric Antigen Receptor (CAR) therapies modify the patient-s own T lymphocytes (autologous) ex vivo and then inject them back into the patient-s body to kill cancer cells. CAR-T cells express hybrid (chimeric) molecules that contain an antibody-binding fragment (scFV) derived from an antibody and intracellular signaling domain(s) from the T-cell receptor. CAR-T cells then bind to specific antigens on the surface of cancer cells resulting in T cell activation and tumor killing.
Typically, a virus is used to introduce the gene for CAR into the T-cells then the cells are activated and amplified ex vivo. The disadvantages of using viral vectors for the delivery of the CAR gene are (i) time-consuming manufacturing that takes 3+ weeks at a GMP facility, (ii) cost ($300K), and (iii) risk of cancer arising from viral integration in host cells.
Description:
Rather than using genes carried by viruses, LLNL researchers have developed an alternative approach of delivering CAR to T-cells in form of proteins that are carried on the surface of nanolipoprotein (NLP) particles. NLPs are naturally occurring molecules that serve as structural mimics of cell membranes. They can self-assemble and provide a structure or platform for connecting other molecules.
CAR proteins integrated into NLPs show high solubility and appropriate binding to their ligand. Culturing T cells with NLPs results in transfer of CAR proteins into human T cells with minimal toxicity, resulting in a population of CAR expressing T cells with no genetic alterations.
For more i... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINTECHNOLOGY/BUSINESS OPPORTUNITY Protein mediated immune cell engineering - USA Tender
The ENERGY, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for TECHNOLOGY/BUSINESS OPPORTUNITY Protein mediated immune cell engineering. This tender is published on USARFP under UST Ref No: 114816299 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-03-14.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
